Your session is about to expire
← Back to Search
Enzalutamide for Early Stage Breast Cancer
Study Summary
This trial is testing whether a year of treatment with the drug enzalutamide can help treat early stage triple negative breast cancer that is positive for the androgen receptor.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2017 Phase 4 trial • 215 Patients • NCT02116582Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My breast cancer has spread to other parts of my body.I am fully active or can carry out light work.I can swallow pills and follow study rules.I am a woman aged 18 or older.I am a woman over 18 and agree to participate in the study.My breast cancer is early stage and lacks ER, PR, and HER2 receptors.I may or may not have had chemotherapy for my breast cancer before.It's been over 4 weeks since my last cancer treatment and any side effects are mild, except for hair loss.I finished my breast cancer treatment within the last 6 months.I haven't had another invasive cancer except for non-dangerous skin cancers or very early stage cancers in the last 5 years.My kidney function is below the normal range.I am eligible for treatment for my early stage breast cancer.My cancer tests positive for androgen receptors.I have a stomach or bowel problem that affects how my body absorbs food.I am allergic to specific ingredients in the medication's capsule.My breast cancer is early stage and lacks ER, PR, and HER2 receptors.I can have AR testing while receiving other cancer treatments.Your bilirubin levels are too high, or your AST or ALT levels are too high.I have a history of seizures or conditions that could lead to seizures.Your white blood cell count, platelet count, or hemoglobin level is too low.
- Group 1: Enzalutamide
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has Enzalutamide been given the stamp of approval by the FDA?
"The safety of enzalutamide was rated a 2 as this Phase 2 trial has some data indicating its security but no evidence that it is effective."
What is the scope of enrolment for this research trial?
"Unfortunately, this research project is not presently enrolling new participants. The trial was initially published on May 19th 2016 and its details were most recently updated in April 26th 2022. For those looking for other studies related to breast cancer, there are currently 2,666 active clinical trials recruiting individuals with the condition; 98 of these involve Enzalutamide therapy specifically."
How many locales provide access to this clinical trial?
"Presently, this medical trial is being administered from 12 sites located in Allentown, Uniondale, New york and other nearby areas. To minimize necessary travel for participants, it is paramount to select the site closest to you."
Are any additional participants being accepted for this research endeavor?
"Data hosted on clinicaltrials.gov suggests that, as of April 26th 2022 this trial is not actively seeking candidates. This investigation was initially posted in May 2016 and has since been inactive; however there are many other studies recruiting patients at this time - 2764 to be exact."
What other research has been conducted with regards to the efficacy of Enzalutamide?
"Currently, there are 98 medical trials underway that investigate Enzalutamide. Of these studies, 30 have progressed to Phase 3 of the trial process. Germantown in Tennessee is home to most of these experiments; however, 5740 other locations across the world also host research on this drug treatment."
Share this study with friends
Copy Link
Messenger